Jun 17, 2020
United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session
Apr 14, 2020
Oxea Increases n-propanol Availability in Europe for Disinfectant Manufacturers and the Printing Industry
Apr 06, 2020
The Global Pulmonary Arterial Hypertension Market is expected to grow from USD 7,196.48 Million in 2019 to USD 9,925.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.50%
Apr 03, 2020
Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal
Mar 05, 2020
Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class And Segment Forecasts, 2020 - 2027
Jan 15, 2020
Visiongain Publishes Global Pulmonary Arterial Hypertension Market 2019-2029 Report
Dec 11, 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Dec 10, 2019
Correvio Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss Brinavess(TM) For Recent Onset Atrial Fibrillation
Nov 04, 2019
Correvio Announces FDA Advisory Committee Meeting to Review Brinavess(TM) for Recent Onset Atrial Fibrillation
Oct 21, 2019
Lutein Market To Reach USD 454.8 Million By 2026 | Reports And Data
Sep 12, 2019
Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application
Jun 26, 2019
Orenitram (treprostinil; United Therapeutics) Market Overview - Newer Brand Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) Poses Tough Competition in the Oral Prostacyclin Class
Jun 26, 2019
Remodulin (treprostinil; United Therapeutics/Mochida) Overview: United Therapeutics is Developing Three New Formulations of Remodulin to Overcome Administration Difficulties